Investing
US FDA approves Biogen-Sage Therapeutics pill for postpartum depression
© Reuters
(Reuters) -The U.S. Food and Drug Administration on Friday approved Biogen (NASDAQ:) and Sage Therapeutics’ oral pill to treat postpartum depression (PPD (NASDAQ:)) in adults.
The companies had sought the FDA’s approval for the drug, Zurzuvae, to treat major depressive disorder), or clinical depression, as well as postpartum depression (PPD), which affect millions of people.
PPD severely affects a woman’s ability to return to normal functioning, while also potentially affecting the mother’s relationship with her child.
Analysts were anticipating the stocks of both companies to fall if the drug was approved only for postpartum depression due to the smaller patient population.
Until now, the FDA said, treatment for postpartum depression was available only as an IV injection.
In 2021, an estimated 21.0 million adults in the United States had at least one episode of major depressive disorder, which is characterized by a persistent feeling of sadness. Postpartum depression (PPD) affects around one in seven women who give birth.
Read the full article here
-
Investing6 days ago
Hurricane Helene Hits Spruce Pine Mine, Quartz Used for Tech
-
Side Hustles7 days ago
5 Key Strategies for a Seamless Cloud Migration
-
Investing7 days ago
Israel stocks lower at close of trade; TA 35 down 0.23% By Investing.com
-
Side Hustles6 days ago
VP Exec’s Top Tips for Negotiating and Relationship-Building
-
Side Hustles7 days ago
Why the Future of Cybersecurity Marketing Relies on Trust
-
Passive Income7 days ago
Go Paperless with the PDF Reader Pro for $49.99
-
Investing6 days ago
Britain’s FTSE 100 rises as oil price jump boosts energy shares By Reuters
-
Side Hustles6 days ago
Why the Smallest Details Mean the Most in Marketing